OnKure (OKUR) Director R. Michael Carruthers Receives Award

What Happened
R. Michael Carruthers, a director of OnKure Therapeutics, was awarded a derivative security on August 7, 2026 covering 22,350 shares. The reported acquisition price is $0.00 (the award/derivative was granted as compensation rather than a cash purchase). No immediate sale or cash exercise is reported.

Key Details

• Transaction date: 2026-08-07; Form 4 filed: 2026-08-11 (timely within the 2-business-day filing window).
• Transaction type/code: A (award/grant of derivative securities).
• Shares/units: 22,350 (derivative right to acquire underlying shares); reported price $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the Issuer’s next annual meeting of stockholders, subject to continued service.
• No 10b5-1 plan, tax withholding, or immediate cashless sale is indicated.

Context
This filing reports a compensatory award (a derivative grant, typically options or restricted stock units) rather than an open-market purchase or sale. Such awards are common for directors as part of compensation; they do not represent an immediate cash outlay or disposition. The award vests in full by the earlier of June 4, 2027 or the day before the next annual meeting, conditioned on continued service.